4.4 Article

EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation

Journal

CURRENT GENE THERAPY
Volume 15, Issue 3, Pages 300-312

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1566523215666150126123642

Keywords

Epithelial mesenchymal transition (EMT); E-cadherin; metastization; PI3K/AKT2/TWIST; RNAi nterference (RNAi)

Funding

  1. Portuguese Science and Technology Foundation [PTDC/SAU-FAR/120453/2010]
  2. Portuguese Science and Technology Foundation Doctoral grant [SFRH / BD / 76270 / 2011]
  3. Ministery of Economy and Competitiveness, Spain [PI14/02079 ISCIII]

Ask authors/readers for more resources

Epithelial Mesenchymal Transition (EMT) is an event where epithelial cells acquire mesenchymal-like phenotype. EMT can occur as a physiological phenomenon during tissue development and wound healing, but most importantly, EMT can confer highly invasive properties to epithelial carcinoma cells. The impairment of E-cadherin expression, an essential cell-cell adhesion protein, together with an increase in the expression of mesenchymal markers, such as N-cadherin, vimentin, and fibronectin, characterize the EMT process and are usually correlated with tumor migration, and metastization. A wide range of micro-environmental and intracellular factors regulate tumor development and progression. The dynamic cross-talk between the adhesion-related proteins such as E-cadherin and the EMT-related transcription factors, with special focus on TWIST, will be discussed here, with the aim of finding a suitable biological pathway to be used as potential target for cancer therapy. Emerging concepts such as the role of the PI3K/AKT/TWIST pathway in the regulation of the E-cadherin expression will be highlighted, since it seems to be consistently involved in cells EMT. The wellknown efficacy of the RNA interference as a tool to silence the expression of specific proteins has come into focus as a strategy to control different tumor sub-populations. Despite the oligonucleotides enormous sensitivity and low in vivo stability, new ( nano) technological solutions are expected to enable RNAi clinical application in cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available